Recombinant Human Epidermal Growth Factor 1 × 10^6 Unitis / Mg Bioactivity By Balb/C 3T3 Cell Assay

Recombinant Human Epidermal Growth Factor 1 × 10^6 Unitis / Mg Bioactivity By Balb/C 3T3 Cell Assay​

Description

EGF is a kind of biological protein, so it has a certain biological activity. In the field of cell culture, we measured the bioactivity of rhEGF on the basis of the principle that human EGF can promote the proliferation of mouse embryonic fibroblasts (Balb / c3T3 cells). rEGF is determined by cell prolifiration assay using Balb/c,ED50 ≤ 1ng / ml, corresponding to the biological activity value> 1×10^6Untis / mg. The appearance of our EGF powder is white color, which is the same as the HSA derived from E.coli. 

Quick detail

1. CAS No.: 62253-63-8
2. Place of Origin: Wuhan, China (Mainland)
3. Brand Name: Oryzogen
4. Model Number: HYC020M01
5. Physical Appearance: white lyophilized powder
6. Formulation: rEGF is lyophilized with mannitol as the stabilizer
7. Endotoxin: Less than 1.0 EU/mg
8. Storage and Handling: Stored at temperatures -20℃ for 24 months

Advantages 

1. Healthgen Biotech recombinant Human Epidermal Growth Factor(rhEGF) is free of animal origin, which effectively avoid any potential risk of animal bacteria, prions, virus and contagious protein disease.

2. Healthgen Biotech recombinant Human Epidermal Growth Factor (rhEGF) has excellent batch consistency. Using the world's advanced facility and top production proceeding to extract and purify the rhEGF, Healthgen Biotech can ensure the excellent consistency of rhEGF from different batches.

Supplemental Description 

Healthgen Biotech, always pay great attention to the original technological innovation and intellectual property protection, has the titles of “Hubei Province Molecular Pharmaceutical Engineering Research Center” and “Protein Purification Research Center”. The rice endosperm cell high expression technology platform and other core technology have applied and gained 13 domestic and international patents; and won the “2012 Hubei Provincial Science and technology invention Award”, “2013 National Science and Technology Invention Award and China Patent Excellence Award’. The project obtained the funding from the National Ministry of science and high technology “863 plan”, Major national science and technology plan “Major projects of new varieties of genetically modified organisms” and “Major projects for new drug discovery”, the National Development and Reform Commission “Pilot development of strategic emerging industries”, National Ministry of science and technology innovation fund and state and local plans for all kinds of talented people funding. In July 2015, Healthgen Biotech became a public company on the "China New OTCBB", a national share transfer system for SMEs and officially known as the National Equities Exchange and Quotations, which is the “first stock” of the plant-derived pharmaceutical in China and even the world.